It’s been literally years of waiting for Canadian specialty pharma company Knight Therapeutics (Knight Therapeutics Stock Quote, Charts, News, Analysts, Financials TSX:GUD) to let the proverbial dogs out and now, with a new CEO at the helm, shareholders may be wondering where GUD is headed. Portfolio manager Jason Mann says the future may still be […]
Pharmaceutical companies aren’t every investor’s jam, what with their risk/reward meter at the upper end of the register. But fear not, here are three analysts’ picks from the Canadian pharma space that are worth a look. We start, in no particular order, with clinical-stage biopharma company Zymeworks (Zymeworks Stock Quote, Charts, Analysts, News, Financials NYSE:ZYME), […]
Share
